HUTCHMED (China) Limited (NASDAQ:HCM) Position Increased by State Street Corp

State Street Corp boosted its position in shares of HUTCHMED (China) Limited (NASDAQ:HCM) by 0.9% in the third quarter, Holdings Channel.com reports. The firm owned 349,524 shares of the company’s stock after purchasing an additional 3,078 shares during the period. State Street Corp’s holdings in HUTCHMED were worth $6,826,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. M&G PLC increased its stake in shares of HUTCHMED by 98.1% during the 3rd quarter. M&G PLC now owns 267,231 shares of the company’s stock worth $5,345,000 after purchasing an additional 132,333 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in HUTCHMED by 74.8% in the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock worth $2,248,000 after purchasing an additional 56,200 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in HUTCHMED by 99.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after buying an additional 24,245 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in HUTCHMED during the third quarter valued at about $421,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in shares of HUTCHMED in the third quarter worth about $328,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered HUTCHMED from a “buy” rating to a “hold” rating in a report on Monday, November 18th.

HUTCHMED Price Performance

NASDAQ:HCM opened at $14.27 on Friday. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. HUTCHMED has a 1 year low of $11.93 and a 1 year high of $21.92. The firm’s fifty day simple moving average is $17.45 and its 200 day simple moving average is $18.01.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.